Evidence map›Paper›PMID 35648157›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2022

Histamine research advancements in the second year of the COVID-19 pandemic: report of the European Histamine Research Society (EHRS).

Ilona Obara, João Paulo S Fernandes, Ekaterini Tiligada

Abstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ilona ObaraSchool of Pharmacy and Translational and Clinical Research Institute, The Faculty of Medical Sciences, Newcastle University, King George VI Building, Newcastle upon Tyne, NE1 7RU, UK. ilona.obara@ncl.ac.uk.ORCID http://orcid.org/0000-0002-8906-2771
João Paulo S FernandesDepartament of Pharmaceutical Sciences, Universidade Federal de São Paulo, Diadema, Brazil.ORCID http://orcid.org/0000-0002-9089-273X
Ekaterini TiligadaDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-4620-8398

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the light of cancellation of the 50th Annual Meeting of the European Histamine Research Society (EHRS) due to continuing challenges and restrictions imposed by the coronavirus disease 2019 (COVID-19) outbreak, the EHRS Council decided to organize a series of online events spread in 2021 to allow dissemination of histamine research progress and advancement among the Society members and beyond. This report summarizes the outcomes of the EHRS Council initiative that comprised the organization of four webinars, each focusing on a highly relevant histamine research scientific area. These included insights into novel therapeutic targets related to the histaminergic system in the eye, histamine intolerance, and the role of histamine and the histaminergic system in the regulation of the nervous system, as well as an update on studies leading to the development of novel methods for histamine detection. The outcome of this series of virtual events conformed that histamine research continued to develop despite the pandemic, and we witnessed stimulating advancements in 2021. Importantly, the EHRS Council brought histaminologists together in this unprecedented time.

Indexed as

COVID-19PandemicsHistamineHumansHistamine

Identifiers

PMID35648157
PMCPMC9158306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.